TAK – takeda pharmaceutical company limited american depositary shares (each representing 1/2 of a share of) (US:NASDAQ)
Stock Stats
News
12/19
08:08 am
tak
Low
Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative [Globe and Mail, The (Toronto, Canada)]
12/12
05:30 pm
tak
Low
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
12/11
07:14 pm
tak
Low
Dietary Supplements Market in Japan is Expected to Reach USD 2,310.30 Million by 2033, Growing at a 6.2% CAGR | Future Market Insights, Inc. [Yahoo! Finance]
12/10
04:12 am
tak
Low
Takeda Pharmaceutical (TSE:4502) Advances with New Product Update and Strategic Alliances for Growth [Yahoo! Finance]
12/3
07:00 am
tak
Low
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
12/18
06:01 am
tak
Low
Form 6-K TAKEDA PHARMACEUTICAL For: Dec 18
12/13
06:13 am
tak
Low
Form 6-K TAKEDA PHARMACEUTICAL For: Dec 13
12/2
06:02 am
tak
Neutral
Form 6-K TAKEDA PHARMACEUTICAL For: Dec 02
10/31
06:29 am
tak
Low
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 31
10/31
06:21 am
tak
Low
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 31
Show more
Top News Gainers
3/2 Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer 5.1%
4/6 European Commission Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ NSCLC 4.9%
7/31 Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful Integration 4.9%
3/4 Takeda Completes Sale of Select OTC and Non-Core Assets to STADA 4.8%
4/10 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $18.00 price target on the stock. 4.1%
5/9 Asia Markets: Asian markets mostly gain despite looming U.S. tariff hikes targeting Chinese goods [MarketWatch] 4.1%
11/1 Takeda Pharmaceutical Co. Ltd (TKPHF) CEO Christophe Weber on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 3.8%
4/27 Takeda ProThera Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] 3.8%
2/4 Japan's Takeda forecasts surprise full-year operating profit [Yahoo! Finance News] 3.2%
5/17 Canadian Blood Services warns of imminent shortage of take-home immune globulin drug [Toronto Globe and Mail (Ontario, Canada)] 3.1%
Top News Decliners
3/17 The Lancet publishes papers from two studies of Takeda’s dengue vaccine candidate -10.1%
5/14 Takeda forecasts operating loss as Shire integration costs mount [FT.com - Mergermarket] -8.0%
2/26 Form POS AM TAKEDA PHARMACEUTICAL -6.6%
10/21 Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFa Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease -5.0%
11/9 2 Biotech Stocks Fighting Alzheimer’s Disease to Own Now [The Motley Fool] -4.0%
5/16 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -3.6%
11/8 New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period -3.6%
7/9 Takeda Continues Ongoing Inclusion in the FTSE4Good Developed Index & MSCI ESG Leaders Index -3.0%
3/4 Japan's Takeda Pharma says it is developing coronavirus drug [Reuters (UK)] -2.7%
3/4 Japan stocks track Wall Street higher, but virus worries weigh [Reuters] -2.7%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3